drugset / Trial / NCT02183389

Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers

NCT02183389

Phase 1 Completed 18 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To investigate whether and to what extent BI 1356 affects pharmacokinetic and pharmacodynamic parameters of warfarin

Timeline

Start
2008-05
Primary completion
2008-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule 5 mg Oral
Subject Warfarin Small molecule 10 mg Oral

Indications

No indication recorded.